↓ Skip to main content

Dove Medical Press

Timosaponin B-II ameliorates diabetic nephropathy via TXNI P, mTOR, and NF-κB signaling pathways in alloxan-induced mice

Overview of attention for article published in Drug Design, Development and Therapy, November 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user
facebook
1 Facebook page

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
24 Mendeley
Title
Timosaponin B-II ameliorates diabetic nephropathy via TXNI P, mTOR, and NF-κB signaling pathways in alloxan-induced mice
Published in
Drug Design, Development and Therapy, November 2015
DOI 10.2147/dddt.s96435
Pubmed ID
Authors

Yong-Liang Yuan, Chang-Run Guo, Ling-Ling Cui, Shi-Xia Ruan, Chun-Feng Zhang, De Ji, Zhong-Lin Yang, Fei Li

Abstract

Many synthesized drugs with clinical severe side effects have been used for diabetic nephropathy (DN) treatment. Therefore, it is urgent and necessary to identify natural and safe agents to remedy DN. Timosaponin B-II (TB-II), a major steroidal saponin constituent in Anemarrhena asphodeloides Bunge, exhibits various activities, including anti-inflammatory and hypoglycemic functions. However, the anti-DN effects and potential mechanism(s) of TB-II have not been previously reported. To investigate the effect of TB-II on DN in alloxan-induced diabetic mice. TB-II was isolated and purified from A. asphodeloides Bunge using macroporous adsorption resin and preparative high-performance liquid chromatography. The effect of TB-II on DN was evaluated in alloxan-induced diabetic mice using an assay kit and immunohistochemical determination in vivo. The expression of mammalian target of rapamycin (mTOR), thioredoxin-interacting protein (TXNIP), and nuclear transcription factor-κB (NF-κB) signaling pathways was also measured using Western blot analysis. TB-II significantly decreased the blood glucose levels and ameliorated renal histopathological injury in alloxan-induced diabetic mice. In addition, TB-II remarkably decreased the levels of renal function biochemical factors, such as kidney index, blood urea nitrogen, serum creatinine, urinary uric acid, urine creatinine, and urine protein, and it reduced lipid metabolism levels of total cholesterol and triglycerides and the levels of inflammatory cytokines interleukin-6 and tumor necrosis factor-α in alloxan-induced mice. Furthermore, TB-II inhibited the expression of mTOR, TXNIP, and NF-κB. The results revealed that TB-II plays an important role in DN via TXNIP, mTOR, and NF-κB signaling pathways. Overall, TB-II exhibited a prominently ameliorative effect on alloxan-induced DN.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 21%
Researcher 3 13%
Student > Master 2 8%
Professor 2 8%
Librarian 1 4%
Other 2 8%
Unknown 9 38%
Readers by discipline Count As %
Medicine and Dentistry 6 25%
Agricultural and Biological Sciences 3 13%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Biochemistry, Genetics and Molecular Biology 1 4%
Nursing and Health Professions 1 4%
Other 2 8%
Unknown 9 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2015.
All research outputs
#19,962,154
of 25,394,764 outputs
Outputs from Drug Design, Development and Therapy
#1,314
of 2,270 outputs
Outputs of similar age
#201,920
of 294,905 outputs
Outputs of similar age from Drug Design, Development and Therapy
#56
of 103 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,270 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,905 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 103 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.